ESPR
Esperion Therapeutics, Inc. [ESPR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ESPR Stock Summary
In the News
ESPR Financial details
Company Rating
-
Market Cap
364.69M
Income
-236.75M
Revenue
116.33M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
240
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-1.25
Forward P/E
-
PEG
0.29
P/S
3.08
P/B
-0.76
P/C
-
P/FCF
-2.25
Quick Ratio
1.14
Current Ratio
1.58
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.47
EPS next Y
-
EPS next Q
-
EPS this Y
-53.12%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-12.77%
Revenue last 5Y
-4.75%
Revenue Q/Q
-5.06%
EPS Q/Q
35.14%
-
-
-
-
SMA20
0.32%
SMA50
16.73%
SMA100
-5.42%
Inst Own
-
Inst Trans
-
ROA
-112%
ROE
28%
ROC
-1.86%
Gross Margin
65%
Oper. Margin
-151%
Profit Margin
-242%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.7-3.4
52W High
-
52W Low
-
RSI
70.75
Rel Volume
1.67
Avg Volume
6.71M
Volume
11.23M
Perf Week
0.32%
Perf Month
57.5%
Perf Quarter
-17.11%
Perf Half Y
-17.75%
-
-
-
-
Beta
0.822
-
-
Volatility
0.01%, 0.01%
Prev Close
0%
Price
3.15
Change
0.32%
Company Profile
- Volume Average 6.71M
- Market Capitalization 364.69M
- Employee 240
- CEO Mr. Sheldon L. Koenig
- Headquarters Ann Arbor,MI,US
- IPO Date 2013-06-26
-
Website
https://www.esperion.com 
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
